Mascoma Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Mascoma Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$8.89K	Buy	17 +3	+21%	+$1.54K	﹤0.01%	342
2026 Q2	$6.95K	Sell	14 -3	-18%	-$1.33K	﹤0.01%	351
2026 Q1	$7.59K	Hold	17	–	–	﹤0.01%	341
2025 Q4	$7.71K	Buy	17 +3	+21%	+$1.29K	﹤0.01%	338
2025 Q3	$5.48K	Hold	14	–	–	﹤0.01%	367
2025 Q2	$6.23K	Hold	14	–	–	﹤0.01%	368
2025 Q1	$6.79K	Hold	14	–	–	﹤0.01%	371
2024 Q4	$5.64K	Buy	+14	New	+$6.49K	﹤0.01%	396

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Provident Investment Management Novi, Michigan $999M AUM 19.45% 1-Year Est. Return

Mascoma Wealth Management's VRTX Position: Q3 2026 in Review

Mascoma Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 21% in Q3 2026, buying an estimated $1.54K and bringing the position to 17 shares worth $8.89K. The position accounts for ﹤0.01% of the portfolio, ranked #342.

Mascoma Wealth Management first reported a position in VRTX in Q4 2024 and has held it in 8 quarters since. 495 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Mascoma Wealth Management held 17 shares of Vertex Pharmaceuticals worth $8.89K as of Q3 2026.
Mascoma Wealth Management bought 3 Vertex Pharmaceuticals shares in Q3 2026, an estimated $1.54K.
Vertex Pharmaceuticals made up ﹤0.01% of Mascoma Wealth Management's portfolio in Q3 2026, its #342 holding.
Mascoma Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
495 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Mascoma Wealth Management's 13F filing for Q3 2026, filed 23 Oct 2026.